Biopeople becomes Danish ScanBalt Liaison Office

Feb 27, 2012

Biopeople becomes Danish ScanBalt Liaison Office Biopeople today is welcomed as Danish liaison office for ScanBalt BioRegion at a ceremony in Copenhagen. Biopeople is part of the permanent Danish infrastructure for innovation established and co-funded by the Danish Agency for Science, Technology and Innovation and the Danish Council for Technology and Innovation. Biopeople embraces universities, research organisations, and hospitals, the Danish Medicines Agency, industry associations as well as pharma, medtech, medical device, food and biotech companies. Key objectives of the liaison office are to promote the attraction of EU and other investments to regional Danish hubs via collaborations in ScanBalt ...

Read More

Flanders – An attractive BioPharma Cluster.

Feb 25, 2012

Flanders – An attractive BioPharma Cluster. Innovation is the key word for the life sciences and biotechnology sector. Flanders has a long and successful tradition of discovery and innovation. Joke Comijn of FlandersBio explores some of the major scientific breakthroughs achieved, including the first unravelling of the DNA sequence of a gene, the discovery of tPA, a major treatment for heart failure, and the discovery of treatments for schizophrenia, pain management, gastro-intestinal disorders and parasitic infections. Innovation combined with entrepreneurship, the presence of a life sciences network of more than 145 companies with biotech activities, and numerous biopharma collaborations, have ...

Read More

Clinical Trials Insurance: Integrated Expertise and Technology Enable Precise Aim at a Moving Target

Feb 25, 2012

Clinical Trials Insurance: Integrated Expertise and Technology Enable Precise Aim at a Moving Target Clinical trials have gone global. According to the National Institutes of Health, a division of the US Department of Health and Human Services, there are currently more than 58,000 trials taking place in more than 150 countries. One of the main challenges life sciences companies face, however, is keeping abreast of the various insurance requirements imposed by these countries. Kathleen Burns of Aon eSolutions discusses what needs to be considered when securing appropriate clinical trials insurance, especially for multinational sites. More. ...

Read More

Patent Data – Why More is More

Feb 25, 2012

Patent Data – Why More is More In order to obtain a patent, it is necessary to show that your invention is novel and inventive. One aspect of this is that the invention should make a contribution to the relevant field of research. As a result, when a patent application is filed, it ought to contain data, usually in the form of experimental results, to convince the patent office that this is the case. Care must be taken to ensure that in the rush to secure an early filing date, the need to ensure that sufficient data is included in ...

Read More

Quality Staff Recruitment and Retention.

Feb 25, 2012

Quality Staff Recruitment and Retention. In 2009 the pharmaceutical industry was affected just the same as everyone else by the economic downturn. Biotechnology companies found their funding being withdrawn or just not being there in the first place; large pharma suffered from drug pipelines drying up; and the related services industries found it difficult to win work, with their margins being squeezed hard by clients who found themselves in a very strong bargaining position. Jim Gleeson from CK Clinical explores from a purely recruitment perspective a number of effects of this turmoil. More ...

Read More